PDF(Pubmed)
Abstract：
UNASSIGNED: Malignant tumors are diagnosed using various methods, including diagnostic imaging methods. The measurement of tumor markers is commonly used because of its noninvasiveness and convenience. Furthermore, it is known that the excretion and metabolism of some tumor markers are affected by impaired renal function. In the present study, we investigated the effect of improved renal function on pre-and post-transplantation changes in tumor marker levels [carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), and prostate-specific antigen (PSA)] in renal transplant recipients.
UNASSIGNED: A total of 116 renal transplant recipients, who had not been diagnosed with malignancies between January 2012 and December 2019, were included, and tumor markers were investigated.
UNASSIGNED: CEA showed a significant decrease after kidney transplantation, regardless of the dialysis type (3.6→2.6 ng/ml, p<0.001), while other tumor markers showed a significant increase (AFP: 3.6→3.7 ng/ml; CA19-9: 16.2→19.5 U/ml; PSA: 0.95→1.05 ng/ml; all p<0.05). Pre- and postoperative eGFR ratios and postoperative liver function were identified as factors influencing the postoperative CEA and CA19-9 values, while PSA was influenced by the duration of dialysis. No statistically significant factors were found for AFP levels.
UNASSIGNED: Caution should be exercised when investigating tumor markers in patients with renal dysfunction, as tumor marker levels may vary depending on the pathophysiology of each patient.
UNASSIGNED: A total of 116 renal transplant recipients, who had not been diagnosed with malignancies between January 2012 and December 2019, were included, and tumor markers were investigated.
UNASSIGNED: CEA showed a significant decrease after kidney transplantation, regardless of the dialysis type (3.6→2.6 ng/ml, p<0.001), while other tumor markers showed a significant increase (AFP: 3.6→3.7 ng/ml; CA19-9: 16.2→19.5 U/ml; PSA: 0.95→1.05 ng/ml; all p<0.05). Pre- and postoperative eGFR ratios and postoperative liver function were identified as factors influencing the postoperative CEA and CA19-9 values, while PSA was influenced by the duration of dialysis. No statistically significant factors were found for AFP levels.
UNASSIGNED: Caution should be exercised when investigating tumor markers in patients with renal dysfunction, as tumor marker levels may vary depending on the pathophysiology of each patient.
摘要：
■恶性肿瘤的诊断使用各种方法，包括诊断成像方法。肿瘤标志物的测量由于其非侵袭性和便利性而被普遍使用。此外，众所周知，某些肿瘤标志物的排泄和代谢受到肾功能受损的影响。在本研究中,我们调查了肾功能改善对移植前后肿瘤标志物水平变化的影响[癌胚抗原（CEA），甲胎蛋白（AFP），糖类抗原19-9(CA19-9),和肾移植受者的前列腺特异性抗原（PSA）]。
■共有116名肾移植受者，在2012年1月至2019年12月期间未被诊断出患有恶性肿瘤的人，包括在内，和肿瘤标志物进行了调查。
■肾移植后CEA显著下降，无论透析类型如何(3.6→2.6ng/ml，p<0.001)，而其他肿瘤标志物显示显着升高（AFP：3.6→3.7ng/ml；CA19-9：16.2→19.5U/ml；PSA：0.95→1.05ng/ml；所有p<0.05）。术前和术后eGFR比值和术后肝功能被确定为影响术后CEA和CA19-9值的因素，而PSA受透析时间的影响。AFP水平没有发现统计学上有意义的因素。
■在研究肾功能不全患者的肿瘤标志物时应谨慎行事，因为肿瘤标志物水平可能根据每个患者的病理生理学而变化。
■共有116名肾移植受者，在2012年1月至2019年12月期间未被诊断出患有恶性肿瘤的人，包括在内，和肿瘤标志物进行了调查。
■肾移植后CEA显著下降，无论透析类型如何(3.6→2.6ng/ml，p<0.001)，而其他肿瘤标志物显示显着升高（AFP：3.6→3.7ng/ml；CA19-9：16.2→19.5U/ml；PSA：0.95→1.05ng/ml；所有p<0.05）。术前和术后eGFR比值和术后肝功能被确定为影响术后CEA和CA19-9值的因素，而PSA受透析时间的影响。AFP水平没有发现统计学上有意义的因素。
■在研究肾功能不全患者的肿瘤标志物时应谨慎行事，因为肿瘤标志物水平可能根据每个患者的病理生理学而变化。
